Current partner codePEPTIDESDE
NCT07566455·Phase 4·INTERVENTIONAL

Comparing Intra-Umbilical Versus Intravenous Oxytocin in Women During the Third Stage of Labor for Reducing Blood Loss

Status

Completed

Phase

Phase 4

Enrollment

60

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The goal of this clinical trial is to determine whether giving oxytocin through the umbilical cord is more effective than giving it through a vein in reducing blood loss during the third stage of labor. The third stage of labor is the period between the birth of the baby and the delivery of the placenta. Excessive bleeding after delivery, known as postpartum hemorrhage, is a major cause of maternal illness and death worldwide. Oxytocin is commonly used to help the uterus contract and reduce bleeding after childbirth. The main question this study aims to answer is: Does intra-umbilical oxytocin reduce the average amount of blood loss during the third stage of labor compared with intravenous oxytocin? Researchers will conduct a randomized controlled trial involving 60 women with uncomplicated pregnancies who are in spontaneous labor. Participants will be randomly assigned to one of two groups. Participants in the first group will receive 10 IU oxytocin intravenously at the delivery of the baby's anterior shoulder. Participants in the second group will receive 10 IU oxytocin injected into the umbilical cord after the baby is delivered. In both groups, the placenta will be delivered using controlled cord traction. Blood loss will be measured by collecting blood in a kidney tray and by weighing pre-weighed sanitary pads for the first 24 hours after delivery. Researchers will compare the average blood loss between the two groups to determine which method of administering oxytocin is more effective in reducing postpartum bleeding.

Interventions

Treatment arms and agents.

DRUG

Oxytocin after delivery

10 IU oxytocin diluted in normal saline administered slowly via intravenous route at the time of delivery of the anterior shoulder to facilitate uterine contraction and reduce blood loss.

DRUG

Intraumbilical oxytocin

10 IU oxytocin diluted in 10 mL normal saline injected into the umbilical vein approximately 2 cm from the introitus after delivery of the baby, with the solution gently milked toward the placental insertion to promote placental separation and reduce blood loss.

Timeline

From registration to results.

  1. First posted

    May 5, 2026

  2. Study start

    Aug 13, 2025

  3. Primary completion

    Feb 12, 2026

  4. Study completion

    Feb 12, 2026

  5. Results posted

    Not reported

  6. Registry updated

    May 5, 2026

Outcomes

What the study measures.

Primary outcomes

Mean Blood Loss During the Third Stage of Labor and Within the First 24 Hours After Vaginal Delivery

Time frame · From delivery of the baby until 24 hours postpartum

The average amount of blood lost after delivery will be measured in milliliters. Blood loss will be collected in a kidney tray immediately after delivery and quantified using a graduated cylinder. Additional blood loss during the first 24 hours postpartum will be measured using pre-weighed sanitary pads (1 gram weight increase = 1 mL blood loss).

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
20 Years
Maximum age
40 Years
Sex
FEMALE
Healthy volunteers
No

Inclusion Criteria: * Gestational age 36 - 42 weeks (on LMP) * In spontaneous labour Exclusion Criteria: * Chronic hypertension * Pre-eclampsia * Multiple pregnancies * Preterm or postdates pregnancy * Previous cesarean section * Diabetes (chronic and gestational) * Fetal macrosomia * History of bleeding / clotting disorder * History of anti-coagulation heparin / warfarin therapy * Non-reassuring cardiotocograph or poor progress of labour

Study locations

1 registered sites.

Pakistan. Showing up to 24 locations stored in the fast local snapshot.

CMH Multan Institute of Medical Sciences

Multan, Punjab Province, Pakistan

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Oxytocin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.